Increases quarterly distributions to the Oregon Criminal Justice Commission for deposit into the Illegal Marijuana Market Enforcement Grant Program Fund from $750,000 to $3 million.
HB 4139 is a cannabis regulation and enforcement bill that makes several changes across Oregon’s medical marijuana, adult-use cannabis, and industrial hemp frameworks. Its most visible fiscal change is to increase the quarterly transfer from the Oregon Marijuana Account to the Oregon Criminal Justice Commission’s Illegal Marijuana Market Enforcement Grant Program Fund from $750,000 to $3 million. The bill also preserves the existing quarterly distribution to the Oregon Liquor and Cannabis Commission for marijuana regulation.
The measure revises key definitions in Oregon cannabis law, including “debilitating medical condition,” by allowing an attending provider to determine that any medical condition or treatment side effect might be mitigated by medical marijuana. It also repeals ORS 475C.913, which had governed a petition-based process for adding conditions, and updates related medical marijuana terminology. In addition, the bill defines “industrial hemp-derived cannabinoid product,” “container,” and adjusts the definition of “adult use cannabis item,” while imposing a retail sales tax on industrial hemp-derived cannabinoid products.
HB 4139 also strengthens oversight and enforcement. It directs the Oregon Liquor and Cannabis Commission and the State Department of Agriculture to conduct certain inspections without advance notice and to request law enforcement accompaniment for those inspections. The bill requires criminal records checks for industrial hemp handler applicants, adds land-use compatibility and land ownership disclosure requirements for industrial hemp grower applicants, and authorizes immediate suspension of a marijuana production license for specified reasons. These changes affect cannabis licensees, hemp businesses, medical marijuana patients, and enforcement agencies.
The general sentiment reflected in the committee vote appears supportive of the bill’s enforcement and regulatory changes, with the House committee voting 9-1 to do pass with amendments. The bill was still in committee when the session adjourned, so it did not complete the full legislative process. The available record shows no transcript debate, but the vote suggests broad committee agreement with the amended package.
The main points of contention likely center on the bill’s tougher enforcement tools, expanded inspection authority, and the new tax on hemp-derived cannabinoid products. Those provisions may be viewed favorably by regulators and law enforcement seeking to curb the illegal marijuana market, but potentially opposed by hemp operators, cannabis businesses, and advocates concerned about increased compliance burdens, warrantless-style inspections, and broader state control over cannabinoid products.
HB 4139 would amend Oregon’s cannabis statutes, primarily ORS 475C.728 and 475C.777, and repeal ORS 475C.913. It would increase the amount of marijuana-account revenue dedicated each quarter to the Illegal Marijuana Market Enforcement Grant Program Fund, expand the medical marijuana eligibility definition, add new regulatory definitions for hemp-derived cannabinoid products, and impose a retail sales tax on those products. It also expands inspection, licensing, and enforcement authority for the OLCC and the Department of Agriculture, affecting marijuana licensees, hemp growers and handlers, and related enforcement and public health oversight systems.
The available voting history suggests the bill was generally well received in committee, with a 9-1 do pass recommendation on the amended version. That indicates substantial support for the bill’s enforcement and regulatory approach, especially the increased funding for illegal market enforcement. Because there are no committee transcript snippets, the record does not show detailed public debate, but the committee action points to a favorable overall sentiment with at least one dissenting view.
The most likely areas of contention are the bill’s increased enforcement funding, expanded inspection powers without advance notice, and the requirement that law enforcement accompany agency inspections in some cases. The new retail sales tax on industrial hemp-derived cannabinoid products may also be controversial among hemp processors and retailers. In addition, the broadened definition of debilitating medical condition could draw differing views from medical marijuana advocates and regulators, though it appears less contentious than the enforcement and tax provisions.